A B S T R A C T The effect of specific immunotherapy on several in vitro responses to ragweed antigen E has been evaluated in 17 atopic patients with ragweed hayfever. The methods employed were leukocyte histamine release, measurement of specific IgE anti-ragweed antibody and specific IgG anti-ragweed antibody, lymphocyte proliferation, and the production of two lymphocyte mediators (migration inhibitory factor and mitogenic factor). The duration of treatment and symptom improvement were also recorded for comparison.
INTRODUCTION
Ragweed hayfever has classically been attributed to mechanisms of immediate hypersensitivity involving reaginic (IgE) antibodies (1) . However, recent evidence suggests that cellular immune responses to ragweed antigen may also be detected (2) (3) (4) (5) (6) (7) (8) . In our previous study (2) we measured a broad range of immunologic responses including antigen-induced leukocyte histamine release, the radioallergosorbent test (RAST)1 for specific IgE antiragweed antibody (IgEAR), lymphocyte proliferation, and the production of two lymphocyte mediators, migration inhibitory factor (MIF) and mitogenic factor (MF). We found that the majority of patients who were sensitive to ragweed antigen E (RAgE) in terms of histamine release and had higher titers of specific IgEAR also demonstrated enhanced lymphocye proliferation and mediator production.
The purpose of the present study was to evaluate the immunologic changes accompanying specific immunotherapy to ragweed antigen in patients with ragweed hayfever. The same immunologic parameters were measured with one addition, the specific IgG antiragweed antibody (IgGAR) (blocking) titers before and after therapy. The results of this study show the immunologic changes resulting from immunotherapy to be com-
METHODS
Patient selection and treatment. 17 of 28 atopic patients from our original study (2) with symptoms of allergic rhinitis in the ragweed pollenation season were successfully restudied after 6-18 mo of immunotherapy. Some attrition resulted from the transfer of patients to other parts of the country or world and only the data from 17 who remained in the Washington area during treatment are included in this study. These patients all had a significantly positive skin test reaction to the intradermal injection of 0.02 ml of a 100-protein nitrogen unit (PNU)/ml aqueous ragweed extract. None of the patients had previously received specific immunotherapy. Immunotherapy with aqueous whole ragweed extract (WRE) was administered in total doses of 1,400-190,000 PNU with a median of 10,500 PNU. This was given over a period of 6-18 mo with a median of 9 mo. The patients were asked to record symptom improvement during the ragweed season immediately following immunotherapy. None of the in vitro tests were done during the ragweed season or the 8-wk period immediately after.
Specific IgEAR titers. The RAST was used to measure serum specific IgEAR before and after treatment (9) . The antigen-cellulose conjugate was prepared with 20% WRE and cyanogen bromide-activated cellulose particles. The immunosorbent purified anti-IgE(Fc), kindly supplied by Doctors C. E. Arbesman and John Wypych, was labeled by the chloramine T method (10) . All samples were tested at the same time and serum from a known ragweed-sensitive patient was included in the experiment as a reference standard. Antigen-induced leukocyte histamine release. The method used was that of Lichtenstein and Osler as modified by May et al. for small amounts of blood (11) . Venous blood samples were collected before and after immunotherapy. Leukocytes were isolated, washed, and suspended in the appropriate buffer. RAgE (kindly supplied by Dr. C. Kirkpatrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health) was added to the cell suspension in amounts of 106-10`1 g/ml by using threefold dilutions. The released histamine was measured by a fluorometric technique. The concentration of antigen required to elicit release of 50% of the total cellular histamine was used as an indication of the cell sensitivity (6 (12) . RAgE was radiolabeled by the chloramine T method. 2 mCi 'I in NaOH (0.01 ml) was used to label 30 jug of RAgE in the presence of 0.05 mg of chloramine T diluted in phosphate-buffered saline (PBS), pH 7.4. The total reaction volume is 0.110 ml. This is mixed exactly 1 min and the reaction stopped by the addition of 0.1 ml of sodium metabisulfite (0.5 mg/ml) in PBS, pH 7.4. The labeled RAgE is suspended in an additional 0.2 ml of PBS (containing 5% BSA and 8 mg/ml potassium iodide). Free 'I is removed by application to a G-25 Sephadex column (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). The specific activity was 5.6 X 10 cpmfltg of 'I-labeled RAgE. There was a highly significant correlation (r' = 0.76; P = < 0.001) between the IgGAR titer and symptom improvement. The IgGAR titer was higher in patients receiving larger total accumulative doses of ragweed extract treatment (r' = 0.49; P = < 0.05). Furthermore, there was an inverse relationship between the increase in IgGAR titer and the decrease in IgEAR titer (r' = 0.57; P <0.05).
Leukocyte histamine release. In Fig. 3 Fig. 4 . The stimulation indices are for autologous plasma before immunotherapy and autologous plasma and homologous plasma after immunotherapy. This index was greater than the mean control response of 3 in all but one of the pretreatment ragweed-sensitive patients. After immunotherapy, 13 of 16 patients had a decrease in this ratio in autologous plasma, and 11 of 16 manifest a decrease in homologous plasma. The mean pretreatment S/C ratio was 20.7. The mean posttreatment S/C ratios were 8.0 in autologous plasma and 9.8 in homologous plasma. In both instances, the decrease in S/C index is significant for paired means, P < 0.005 (t test (Fig. 5) . Ragweed-sensitive patients, in contrast to normal controls, produce greater amounts of MF in vitro in response to RAgE. The highest cpm values obtained from lymphocytes of normal subjects were 7,000. Cells from all but one patient in this study produced significant amounts of MF before immunotherapy. The mean pretreatment value was 30,226 cpm. Immunotherapy was followed by a decrease in MF production in 11 of the study patients. An increase in MF occurred in four of the patients. The mean posttreatment cpm was 13,050. A paired t test of the MF produced before and after treatment did not reveal a statistical difference.
MIF production. Supernates from patient and control lymphocytes activated by RAgE and SK-SD were assayed for MIF before and after immunotherapy. The inhibitory activity of active supernates was considered significant when 20% inhibition of migration of the indicator cells was observed. As seen in Fig. 6 , significant MIF activity was found in 12 of the ragweed patients before immunotherapy. This was reduced to 20% or less in seven patients after immunotherapy. Two patients produced significant amounts of MIF after immunotherapy when they had not done so before. The mean MIF response to RAgE before immunotherapy was 23.2% inhibition, which decreased to 14.6% after treat- ment. This decrease in MIF production was significant (P < 0.05). The patients' cells were also cultured with SK-SD and the amounts of MIF with this antigen before and after immunotherapy were similar.
Effect of immunotherapy on symptoms. All but one of the patients reported symptom improvement in the ragweed season following immunotherapy as compared to the pretreatment ragweed season. Three of the patients reported no symptoms in the posttreatment ragweed season. This treatment response is similar to other previous reports using high-dose therapy (17) (18) (19) (20) (21) (22) (23) (24) . Correlation of P in in vitro assays. Data from the in vitro assays, including the degree of change in these assays following immunotherapy, were ranked. A coefficient of correlation was determined among these changes as well as among the degree of symptom improvement reported and with the amount of immunotherapy employed. There was a highly significant correlation between the increase in IgGAR and the degree of symptom improvement (r' = 0.76; P < 0.001). There was an inverse relationship between the amount of IgGAR and the amount of IgEAR (r' = 0.56; P < 0.05). Furthermore, there was a direct correlation between the increase in IgGAR and the total dose of ragweed extract administered (r' = 0.50; P < 0.05). The decrease in lymphocyte proliferation to RAgE in homologous plasma after immunotherapy correlated with the increase in IgGAR (r' = 0.49; P < 0.05). There were no other correlations noted among the in vitro tests. A summary of the effects of immunotherapy on the immunologic parameters measured in this study is shown in Table I . DISCUSSION Specific immunotherapy is a widely accepted approach to the treatment of pollen-induced allergic rhinitis (17) (18) (19) (20) (21) (22) (23) (24) (25) ; however, the immunologic events responsible for the reported symptomatic improvement are unclear. The purpose of the present study was to examine the possible mechanisms by which immunotherapy might alter immune responsiveness utilizing newly developed in vitro techniques for measuring humoral and cellular hypersensitivity responses. These techniques were employed in a prospective study of ragweed hayfever sufferers before and after specific immunotherapy.
We have confirmed the observations of others that immunotherapy is associated with a decrease in specific IgE antibodies and an increase in specific IgG blocking antibodies (17, 22 We have also confirmed decreased responsiveness of leukocytes for antigen-induced histamine release following specific immunotherapy (22) (23) (24) . Of interest is our observation that this reduction in leukocyte sensitivity does not regularly parallel the quantitative decrease in specific IgEAR. This apparent discrepancy might be explained by individual variation in response to immunotherapy, by variation in the affinity of the IgE antibody for target cells, and by the importance of sensitivity to ragweed antigens other than RAgE in some of the patients.
While ragweed hayfever is usually associated with IgE-mediated responses, we and others have also found that these patients have lymphocytes which are activated by RAgE (2, 7, 8, 27, 28 Recently, important control mechanisms have been described involving a subpopulation of T cells which modulates bone marrow-derived lymphocyte function (32) (33) (34) (35) (36) . The regulatory role is bidirectional and includes T cells, bone marrow-derived lymphocytes, and macrophages (37, 38) . In the present study, immunotherapy induced a suppression in the levels of specific IgEAR, but stimulated the formation of IgGAR. There are several mechanisms that can be postulated to account for suppression of certain humoral and cellular responses and allow others to be expressed. One mechanism might involve the generation of suppressor T cells which could inhibit IgE-producing cells (32, 35) and possibly other lymphocyte functions such as proliferation and mediator production. Since the T helper cells for IgE and IgG antibody production appear to be distinct subpopulations (34) (40) . The response observed in this study to immunotherapy may be characteristic of atopic patients, a state which may also be conditioned by certain HL-A genotypes. It is not clear whether atopic patients are "programmed" to produce IgE antibodies when presented with ragweed pollen as such in the environment and IgG antibodies upon parenteral administration of antigen. In any event, immunotherapy is a clinically useful tool which appears to result in widespread changes in specific immunologic reactivity to the antigen being used to desensitize the patient.
